{"cdcTestId":"2013-0499","testcaseName":"#1 @ 10 yrs, MCV4","vaccineGroup":"MCV","evaluationTestType":"Age: At Absolute Minimum","forecastTestType":"Recommended based on age","assessmentDate":"2022-10-19T00:00:00","patient":{"dob":"2012-10-19T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"MENACTRA","cvx":"114","mvx":"PMC","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"2","earliestDate":"2028-10-19T00:00:00","recommendedDate":"2028-10-19T00:00:00","pastDueDate":"2029-11-15T00:00:00"},"doses":[{"dateAdministered":"2022-10-19T00:00:00","vaccineName":"MENACTRA","cvx":"114","mvx":"PMC","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2013-01-01T00:00:00","dateUpdated":"2020-06-01T11:15:40.166","generalDescription":"This test case describes when dose #1 of a Mening vaccine is administered at age 10 years \u002B 0 months that the dose is considered valid.","changedInVersion":"1.6","reasonForChange":"v1.6: An EIPB clarification has resulted in a change to when dose 2 of MCV should be forecasted and validated.  The second dose must come on or after 16 years (- 4 days) of age to be considered valid.\nv1.2: Same test case as previous version rolled younger to allow for the 10 year clarification by NIPInfo"}